{"analyses":[{"ciLowerLimit":"1.17","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.08","estimateComment":"The odds ratio and 95% CI were estimated using the Mantel-Haenszel method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0044","paramType":"Odds Ratio (OR)","paramValue":"1.897","statisticalComment":"Cochran-Mantel Haenszel chi-square test with β2 macroglobulin level, prior bortezomib, and prior lenalidomide as stratification factors.","statisticalMethod":"Cochran-Mantel Haenszel chi-square test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.4","upperLimit":"90.3","value":"87.1"},{"groupId":"OG001","lowerLimit":"89.7","upperLimit":"95.0","value":"92.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"396"},{"groupId":"OG001","value":"396"}],"units":"Participants"}],"description":"Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or intravenously on days 1, 8, 15, and 22.","id":"OG000","title":"Lenalidomide and Dexamethasone (Rd)"},{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, then escalated to 27 mg/m² on Days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 of every cycle. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 of every cycle.","id":"OG001","title":"Carfilzomib, Lenalidomide, and Dexamethasone (CRd)"}],"paramType":"NUMBER","populationDescription":"ITT analysis set comprised of all randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}